Prostate Cancer Antigen Presentation by HLA-E as a New Target Mechanism for Immunotherapy

Abstract

We investigate a new paradigm for vaccines and immunotherapies of prostate cancer (PCa). We demonstrate that strain 68-1 rhesus cytomegalovirus (RhCMV)-expressing tumor antigens elicit broad CD8+ T cell responses to epitopes presented by non-polymorphic major histocompatibility complex (MHC)-E molecules instead of polymorphic, classical MHC-Ia. Due to the high conservation of MHC-E we were able to show that human PCa cell lines and human primary tumor cells stimulate MHC-E-restricted CD8+ T cells elicited in rhesus macaques (RM) by 68-1 RhCMV expressing prostate acid phosphatase (PAP). We began identifying T cell receptors (TCRs) recognizing PAP-derived peptides presented by MHC-E and characterizing such TCRs. Since MHC-E is non-polymorphic unlike classical MHC type I molecules TCRs expressed by MHC-E-restricted.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2020
Accession Number
AD1108846

Entities

People

  • Klaus Frueh

Organizations

  • Oregon Health & Science University

Tags

DTIC Thesaurus Topics

  • Abstracts
  • Biological Factors
  • Biomedical Research
  • Biotechnology
  • Cell Line
  • Cells
  • Data Analysis
  • Gene Therapy
  • Health
  • Identification
  • Immunotherapy
  • Lymphocytes
  • Medical Personnel
  • Molecules
  • Neoplasms
  • Prostate
  • Prostate Cancer
  • Proteins
  • Stem Cells
  • Therapy
  • Tissues
  • Tumor Cell Line
  • Vaccines

Fields of Study

  • Biology
  • Medicine

Readers

  • Immunology
  • Oncology (Cancer Research).

Technology Areas

  • Biotechnology
  • Biotechnology - Cancer Biotech